The key takeaway from Amgen Inc's earnings call points to significant advancements and optimism in their clinical programs, especially with avacopan, which is being tested in multiple disease areas with significant unmet needs. The management's confidence in their Phase III trials, positive reception in the clinical community, and a robust financial position indicate strong growth potential. However, the stock's immediate impact may be tempered by the focus on future results and timelines extending to 2019-2020 for key data releases, suggesting limited immediate movement in the stock price.

[0]